Luther King Capital Management (LKCM)
RANI icon

Luther King Capital Management (LKCM)’s Rani Therapeutics RANI Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.6K Hold
58,000
– – ﹤0.01% 599
2025
Q4 		$78.3K Hold
58,000
– – ﹤0.01% 603
2025
Q3 		$29K Hold
58,000
– – ﹤0.01% 597
2025
Q2 		$29.8K Hold
58,000
– – ﹤0.01% 584
2025
Q1 		$73.1K Buy
58,000
+25,000
+76% +$37K ﹤0.01% 589
2024
Q4 		$45.2K Sell
33,000
-48,129
-59% -$101K ﹤0.01% 586
2024
Q3 		$175K Buy
81,129
+25,000
+45% +$71.6K ﹤0.01% 591
2024
Q2 		$213K Hold
56,129
– – ﹤0.01% 578
2024
Q1 		$175K Hold
56,129
– – ﹤0.01% 587
2023
Q4 		$186K Hold
56,129
– – ﹤0.01% 567
2023
Q3 		$122K Hold
56,129
– – ﹤0.01% 573
2023
Q2 		$231K Buy
+56,129
New +$261K ﹤0.01% 558

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Luther King Capital Management (LKCM)'s RANI Position: Q1 2026 in Review

Luther King Capital Management (LKCM) held its Rani Therapeutics (RANI) position steady in Q1 2026 at 58,000 shares worth $42.6K. The position accounts for ﹤0.01% of the portfolio, ranked #599.

Luther King Capital Management (LKCM) first reported a position in RANI in Q2 2023 and has held it in 12 quarters since. The position peaked at $231K in Q2 2023. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Luther King Capital Management (LKCM) held 58,000 shares of Rani Therapeutics worth $42.6K as of Q1 2026.
  • Luther King Capital Management (LKCM) left its Rani Therapeutics share count unchanged in Q1 2026.
  • Rani Therapeutics made up ﹤0.01% of Luther King Capital Management (LKCM)'s portfolio in Q1 2026, its #599 holding.
  • Luther King Capital Management (LKCM) first reported a position in Rani Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Luther King Capital Management (LKCM)'s Rani Therapeutics position peaked at $231K in Q2 2023.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q1 2026, filed 11 May 2026.